Breaking News
Get 40% Off 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

Anygen Co Ltd (196300)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
15,580 +280    +1.83%
16:19:03 - Closed. Currency in KRW ( Disclaimer )
  • Volume: 22,063
  • Bid/Ask: 15,550 / 15,560
  • Day's Range: 15,400 - 15,910
Type:  Equity
Market:  South Korea
ISIN:  KR7196300008 
Anygen 15,580 +280 +1.83%

Anygen Co Ltd Company Profile

 
Get an in-depth profile of Anygen Co Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

-

Equity Type

ORD

Anygen Co., Ltd., a bio-venture company, engages in the manufacture and sale of peptide biomaterials and drug raw materials in South Korea and internationally. It develops GMP, generic, custom, and catalog peptides, as well as offers other services. The company is also developing AGM-331 targeted for anti-cancer therapy, currently under pre-clinical development phase; AGM-130 indicated for the treatment of triple negative breast cancer, currently under Phase I development phase; AGM-380 indicated for the treatment of viral infection, currently under pre-clinical development phase; and AGM-290 indicated for the treatment of infections caused by multidrug resistant bacteria, currently under pre-clinical development phase. In addition, it is involved in the development of AGM-212 indicated for the treatment of Type 2 Diabetes, currently under pre-clinical development phase; AGM-217 indicated for the treatment of Type 2 diabetes and obesity, currently under pre-clinical development phase; and AGM-260 indicated for the treatment of Ulcerative colitis, currently under pre-clinical development phase. The company was founded in 2000 and is headquartered in Gwangju-si, South Korea.

Contact Information

Address Gwangju Technopark Room 206, Pilot plant
333, Cheomdan gwagi-ro Buk-gu Gwangju,61008
South Korea
Phone 82 6 2714 1166
Fax 82 6 2714 1188

Top Executives

Name Age Since Title
Jae Il Kim - - CEO & Director
Young Joon Kim - - R&D Director & Director
Chang Hwan Kim - 2019 Executive MD & Director
Ji-Yong Park 56 2017 R&D Director & Director
Hyun-Il Choi 69 - Director of Audit & Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

196300 Comments

Write your thoughts about Anygen Co Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email